Insights EmergeEmerging companies and life sciences news

Press Release · Wellex

New Feasibility Study Finds Encouraging Signals in IC/BPS Symptoms with IC Well

Distributed by Insights Emerge · Originally issued via PRWeb

Positive findings from a 12-week study are now informing a follow-on pilot study

TORONTO, Nov. 18, 2026 — Interstitial cystitis/bladder pain syndrome (IC/BPS) can significantly affect comfort, daily functioning and quality of life, yet it remains a challenging and under-researched condition. In a new 12-week feasibility study, adults taking IC Well experienced encouraging findings in IC/BPS symptom scores and related measures, findings that are now informing a follow-on pilot study.

The non-randomized feasibility study, conducted in partnership with the Interstitial Cystitis Association (ICA) and WELLEX, evaluated IC Well, a multi-ingredient formulation developed to support bladder and urinary health, in adults living with IC/BPS. The study assessed symptom scores, the impact of symptoms on daily life, flare severity, quality of life and exploratory urinalysis measures, while helping identify the most meaningful outcomes to carry forward into future research.

Twenty-eight participants entered the study, including 15 in the IC Well group and 13 in a comparison group. Participants taking IC Well used two capsules twice daily for 12 weeks, while the comparison group completed the same assessments without taking the supplement.

One of the strongest findings was seen in overall IC symptom scores. Using the Interstitial Cystitis Symptom Index (ICSI), where lower scores reflect fewer or less severe symptoms, participants taking IC Well experienced a statistically significant improvement over the 12 weeks, with average scores decreasing from 12.78 at baseline to 10.44. The comparison group changed little over the same period, and the numerical difference between groups favoured IC Well. Because this was a small feasibility study, however, it was not powered to confirm a statistically significant difference between the two groups.

Encouraging signals were also seen in the impact of symptoms on daily life and in flare severity.

Exploratory urinalysis measures were included as an additional component of the study, with changes observed across several markers, including leukocytes, protein, nitrite, pH, specific gravity and bilirubin. Given the size and exploratory nature of the study, these findings will require further investigation to understand their clinical relevance.

Taken together, the findings provide an encouraging early signal and help identify the outcomes that warrant closer study. Importantly, the research evaluated the finished IC Well formula rather than its individual ingredients alone, helping to build product-specific evidence in an area where more patient-centred research is needed.

Based on these positive feasibility findings, WELLEX will be conducting a follow-on pilot study designed to investigate IC Well further. The next phase will build on what was learned in this initial study and help strengthen the evidence base and inform the design of future, more rigorous clinical research.

Media Contact

Ashley Rutledge, Wellex, 1 6473006542, [email protected], Wellex

LinkedIn

SOURCE Wellex

About the Study

The study included adults aged 18–65 with a self-reported healthcare-provider diagnosis of IC/BPS, stable treatment regimens and chronic pelvic pain causing at least moderate interference. The research project was approved by an Institutional Review Board (IRB Approval No. 02406).

The findings are preliminary and exploratory. As a feasibility study, the research was not designed or powered to establish clinical efficacy, and the results should not be interpreted as evidence that IC Well diagnoses, treats, cures or prevents IC/BPS.